Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in HIV vaccine research.

E van der Ryst1

  • 1Pfizer Global Research and Development, Sandwich, Kent, UK. elna_van_der_ryst@sandwich.pfizer.com

Oral Diseases
|August 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.

Antiviral chemistry & chemotherapy·2021
Same author

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc.

Antiviral chemistry & chemotherapy·2021
Same author

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

Clinical pharmacology and therapeutics·2011
Same author

Missing or contradictory answers on questionnaires--a valuable source of information.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2001
Same author

HIV/AIDS-related knowledge, attitudes and practices among South African military recruits.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2001
Same author

[Macaque immunization with virions purified from a primary isolate of the human immunodeficiency virus type 1 induced enhancement antibodies].

Bulletin de l'Academie nationale de medecine·2000
Same journal

Authors' Reply "Synchronous Soft-Tissue Lesions in the Oral Cavity in an Adolescent".

Oral diseases·2026
Same journal

Neutrophils From Aged Individuals Release NETs to Impair Oral Wound Healing Through NLRP3 Activation.

Oral diseases·2026
Same journal

Comment on "Multimodal Deep Learning-Based Screening of Degenerative Temporomandibular Joint Disease Using 2D Radiography: A Cost-Effective and Low-Radiation Approach".

Oral diseases·2026
Same journal

Oral Lesions and Dental Status in Individuals Using Oral Tobacco-Free Nicotine Pouches.

Oral diseases·2026
Same journal

Comment on "Synchronous Soft-Tissue Lesions in the Oral Cavity in an Adolescent".

Oral diseases·2026
Same journal

Atypical Whitish Gingival Plaque.

Oral diseases·2026
See all related articles

Developing an effective HIV vaccine remains challenging, requiring a multifaceted immune response. While progress shows promise in animal models, further research is crucial for long-term protection against diverse HIV strains.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • The global expansion of the Human Immunodeficiency Virus (HIV) pandemic underscores the urgent need for a preventive vaccine.
  • Developing an effective HIV vaccine presents significant scientific challenges due to the virus's complexity and diversity.

Purpose of the Study:

  • To review the current state of HIV vaccine development, highlighting the requirements for an effective vaccine.
  • To discuss the progress made in animal models and identify remaining hurdles for successful vaccine design.

Main Methods:

  • Review of existing literature on HIV vaccine research and development.
  • Analysis of immune responses induced by prototype vaccines in preclinical studies.
  • Evaluation of protection observed in animal models against various forms of HIV challenge.

Related Experiment Videos

Main Results:

  • Chimpanzees demonstrated protection against both cell-free and cell-associated HIV, including mucosal challenge.
  • Limited cross-protection between different HIV subtypes was observed in animal models.
  • Current prototype vaccines induce short-lived immune responses and lack neutralizing antibodies against clinical HIV-1 isolates.

Conclusions:

  • An effective HIV vaccine likely requires a combination of approaches to elicit neutralizing antibodies, cytotoxic T-lymphocytes, and mucosal immunity.
  • Novel strategies for antigen production may enhance antibody responses and improve the prospects for long-term protective immunity.
  • Significant advancements have been made, but substantial work remains to achieve a broadly protective and durable HIV vaccine.